Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
This includes 14.3 million views on YouTube and 9.8 million views on Meta platforms to amplify preventive heart health message
Analysts expect modest revenue growth but pressure on profitability in the March quarter
The ninth edition of the event brought together over 800 delegates, more than 60 national and international speakers, and 20+ partner organisations across 10 sessions
The campaign builds on the three-year partnership unveiled earlier this season
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
Board approves five-year appointment, subject to shareholder nod through postal ballot
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
Subscribe To Our Newsletter & Stay Updated
